Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368511
Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.
Compound shall mean morphine sulfate and/or morphine polystyrene.
Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product
KADIANÂ® NT shall mean the abuse deterrent form of the KADIANÂ® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.
Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIANÂ® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.
Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.
Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIANÂ® solid dose product line.
IPSCIO Record ID: 338651
Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.
The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
The exclusive license includes Licensorâ€™s LiquiTimeÂ® Ibuprofen and LiquiTimeÂ® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant. These are the initial products.
IPSCIO Record ID: 203528
Patent Rights means
Application Serial No. 09/554,102 Filed May 4, 2000
Application Serial No. 09/555.095 Filed May 24, 2000
IPSCIO Record ID: 2939